Business Wire

CIVITAS-INVESTMENT

Share
Civitas Investment Management Limited: Leading UK Social Impact Investment Manager Launches with AUM of £2 billion

From today all the investment management activities of the Civitas Group have been brought together under the new name of Civitas Investment Management Limited (“CIM” or “the Group”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005883/en/

CIM is a leading impact investor specialising in government-backed real assets that produce beneficial and sustainable social outcomes. Today, CIM announces expanded client mandates with combined assets under management (“AUM”) of £2 billion.

In all of CIM’s investment activities the Group aims to achieve measurable social impact at scale whilst delivering consistent long-term return profiles for investors together with value for money for the public purse. This is reflected in better personal outcomes and an enhanced quality of life for people living in the Group’s properties.

CIM’s performance in achieving these aims is monitored by independent social impact consultants who challenge and assist CIM in its investment frameworks.

Having established a leading presence in the UK for care-based housing and healthcare CIM is now expanding further into community based infrastructure and is planning to launch in the EU during the next 12 months.

New Website

To support these plans CIM has launched a new dedicated website that outlines its activities, social objectives and profiles the range of investment strategies that are delivered for institutional investors around the world (www.civitasim.com ).

Who We Are

CIM is a pioneer in introducing ethical, long-term private capital into the affordable housing and healthcare sectors, initially in England and Wales, then more widely in the UK and now with plans to access major EU countries.

In 2016 CIM launched Civitas Social Housing PLC, (“CSH”) as the first premium London listed real estate investment trust dedicated to investing in care-based housing for working age adults with long-term healthcare needs.

CSH is now a FTSE 250 company and the leading provider of care-based community housing in the UK with a portfolio of more than 600 buildings independently valued at nearly £900 million. Located across 164 local authority areas, supported by 117 specialist care providers, and 15 housing partners CSH provides bespoke, high quality adapted homes for over 4,200 people.

Reflecting the success of the strategy shareholders recently approved an extension of the CSH investment policy to enable the fund to work directly with the NHS, with other leading care providers and with major charities to provide accommodation and other social properties, in short supply within healthcare real estate.

CIM Investment Strategies

Having commenced investing in care-based social housing, CIM has now evolved a range of four broad and complementary investment strategies as follows:

  • Healthcare
  • Social and Affordable Housing
  • Social Infrastructure
  • Urban Regeneration

Across each of the four investment strategies are common themes and investment objectives that include:

  • 100% governmental income and support
  • Value for money for the public purse
  • Stable long-term cash generation
  • Low volatility and low correlation to economic cycles
  • Measurable social and ESG impact

Exclusive Partnerships

To assist in the delivery of the Group’s investment strategies CIM is pleased to have established exclusive partnerships with a number of leading investment houses and global real estate and infrastructure investors with whom CIM shares common ambitions and objectives.

Today CIM’s partners include:

  • Schroders, the global investment manager responsible for more than £500 billion of client assets across multiple investment strategies. CIM and Schroders are exclusive partners delivering new care-based housing, initially for approximately 2,000 people;
  • A leading Asia based global infrastructure and real estate investor has established an exclusive partnership with CIM to invest in housing based social infrastructure assets

Our Vision

The team of professionals working at CIM comes from a range of different backgrounds each offering expertise and operational experience in healthcare, social housing, real estate, social infrastructure and investment management.

They share a common conviction that responsible private capital can play a transformational role in the delivery of social assets that are themselves designed to enhance lives and communities. By investing for the long-term, with measurable social impact a fundamental requirement, the conditions are created for achieving sustainable and ethical returns for investors.

Andrew Dawber, Group Director at Civitas Investment Management Limited commented:

“We are delighted that CIM has reached an important investment milestone based on a growing number of client mandates. We are greatly encouraged by the opportunities in the near term future as we grow and build out our investment funds, deploying capital in projects in the UK, and in Europe in due course. We are experiencing strong and growing demand from portfolio managers who increasingly recognise the attractions of investing in the asset classes that CIM promotes.

We are especially proud of the team that we have built at CIM who each provide different perspectives towards the same goal, creating sustainable investment returns for the long term in projects that deliver genuine social good at a local level wherever that investment is made.”

-ENDS-

Notes to Editors:

Civitas Investment Management Limited (‘CIM’) is a leading impact investment manager that is dedicated to achieving long-term sustainable returns for the Group’s global investors by acquiring community-based assets that deliver positive social outcomes. CIM’s investments are supported by national governments and local municipalities that are themselves seeking to bring about positive societal change. CIM has an AUM of approximately £2 billion with a target to increase to £4 billion over the next two to three years following the build out of client mandates.

Among other impact investment ventures, CIM is the investment adviser to the London listed Civitas Social Housing PLC (“CSH”), the first dedicated London listed REIT to raise long-term sustainable, institutional capital to invest in care-based social homes and healthcare facilities across the UK. So far CIM has on behalf of CSH completed more than 120 individual transactions to build the largest portfolio of its kind in the UK that has been independently valued at approximately £900 million (www.civitassocialhousing.com ).

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye